CHRS - Company ID 0001512762
The table below shows Coherus BioSciences, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $42.17M | $26.39M | $1.22M | $211.04M | $326.55M | $475.82M |
| Cost of revenue | $13.81M | $8.73M | $438.00K | $70.08M | $57.59M | $37.67M |
| Gross profit | - | - | - | - | - | - |
| R&D | $108.89M | $91.83M | $96.11M | $199.36M | $363.11M | $142.76M |
Coherus BioSciences, Inc. reported annual revenue of $42.17M for fiscal year 2025. That is up 59.8% from $26.39M in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $190.11M (FY 2016) to $42.17M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $100.60M |
| $125.48M |
| $120.46M |
| $198.48M |
| $169.71M |
| $139.08M |
| Operating income | -$181.13M | -$199.65M | -$215.79M | -$256.88M | -$263.86M | $156.32M |
| Income tax | $0.00 | $0.00 | -$380.00K | $0.00 | $0.00 | $3.46M |
| Net income | $168.02M | $28.51M | -$237.89M | -$291.75M | -$287.10M | $132.24M |
| EPS (diluted) | $1.43 | $0.25 | -$2.53 | -$3.76 | -$3.81 | $1.62 |